EXCLUSIVE: TransCode's RNA Therapeutic Achieves 64% Stable Disease Rate In Colorectal Cancer Phase 1 Study

Benzinga_recent_news

06/03

TransCode Therapeutics, Inc. (NASDAQ:RNAZ) announced Wednesday that it has successfully completed the Phase 1a dose-escalation clinical trial of its lead cancer therapeutic candidate, TTX-MC138. It ...

网页链接

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2640904149"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2640904149\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2640904149?lang=zh_CN&edition=fundamental","thumbnail":"https://cdn.benzinga.com/cdn-cgi/image/width=240,dpr=2,format=auto,quality=85/files/images/story/2026/06/03/Cancer---Heart-Shape-To-Represent-Medica.jpeg","is_english":true,"pubTime":"2026-06-03 19:41","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2640904149","market":"us","top_or_hot":-1,"title":"EXCLUSIVE: TransCode's RNA Therapeutic Achieves 64% Stable Disease Rate In Colorectal Cancer Phase 1 Study","media":"Benzinga_recent_news","content":"<div>\n<p>TransCode Therapeutics, Inc. (NASDAQ:RNAZ) announced Wednesday that it has successfully completed the Phase 1a dose-escalation clinical trial of its lead cancer therapeutic candidate, TTX-MC138.\nIt ...</p>\n\n<a href=\"https://www.benzinga.com/news/health-care/26/06/52965529/exclusive-transcodes-rna-therapeutic-achieves-64-stable-disease-rate-in-colorectal-cancer-phase-1-study\">网页链接</a>\n\n</div>\n","source":"benzinga_recent_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>EXCLUSIVE: TransCode's RNA Therapeutic Achieves 64% Stable Disease Rate In Colorectal Cancer Phase 1 Study</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEXCLUSIVE: TransCode's RNA Therapeutic Achieves 64% Stable Disease Rate In Colorectal Cancer Phase 1 Study\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-06-03 19:41 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/news/health-care/26/06/52965529/exclusive-transcodes-rna-therapeutic-achieves-64-stable-disease-rate-in-colorectal-cancer-phase-1-study><strong>Benzinga_recent_news</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>TransCode Therapeutics, Inc. (NASDAQ:RNAZ) announced Wednesday that it has successfully completed the Phase 1a dose-escalation clinical trial of its lead cancer therapeutic candidate, TTX-MC138.\nIt ...</p>\n\n<a href=\"https://www.benzinga.com/news/health-care/26/06/52965529/exclusive-transcodes-rna-therapeutic-achieves-64-stable-disease-rate-in-colorectal-cancer-phase-1-study\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE0009354923.USD","symbol_name":"JANUS HENDERSON US VENTURE \"A2\" (USD) ACC","start_time":0,"source_url":"https://www.benzinga.com/news/health-care/26/06/52965529/exclusive-transcodes-rna-therapeutic-achieves-64-stable-disease-rate-in-colorectal-cancer-phase-1-study","article_id":"2640904149","we_media_id":null,"thumbnails":["https://cdn.benzinga.com/cdn-cgi/image/width=240,dpr=2,format=auto,quality=85/files/images/story/2026/06/03/Cancer---Heart-Shape-To-Represent-Medica.jpeg"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/news/health-care/26/06/52965529/exclusive-transcodes-rna-therapeutic-achieves-64-stable-disease-rate-in-colorectal-cancer-phase-1-study","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2640904149","pubTimestamp":1780486860,"columns":[],"sourceInfo":{"source_id":"benzinga_recent_news","name":"Benzinga"},"weMediaInfo":null,"summary":"TransCode Therapeutics announced successful completion of Phase 1a clinical trial for TTX-MC138, showing safety and disease stabilization in patients with advanced cancer.","collect":0,"end_time":0,"defaultTopTitle":"benzinga.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE0009354923.USD":"JANUS HENDERSON US VENTURE \"A2\" (USD) ACC","RNAZ":"TransCode Therapeutics  Inc.","BK4588":"碎股","BK4539":"次新股","BK4585":"ETF&股票定投概念","BK4505":"高瓴资本持仓","RNA":"Atrium Therapeutics","BK4139":"生物科技"},"translate_title":"独家：TransCode的RNA疗法在结直肠癌1期研究中实现64%的稳定发病率","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RNA":1.5,"RNAZ":1},"content_text":"TransCode Therapeutics, Inc. (NASDAQ:RNAZ) announced Wednesday that it has successfully completed the Phase 1a dose-escalation clinical trial of its lead cancer therapeutic candidate, TTX-MC138.\nIt met its primary safety objectives and demonstrated durable disease stabilization in patients with advanced metastatic cancer.\nThe Boston-based clinical-stage company announced Wednesday that the drug candidate was well-tolerated, showing a complete absence of dose-limiting toxicities across all tested patient cohorts.\nThe positive data support advancing the therapeutic into Phase 2a clinical development.\nThe Phase 1a trial evaluated the safety, tolerability, and pharmacokinetics of TTX-MC138 across a heavily pre-treated patient population.\nThe dose-escalation study evaluated patients across four distinct cohorts, with zero dose-limiting toxicities reported:\nFollowing the successful completion of these cohorts, TransCode has selected 4.8 mg/kg as its recommended Phase 2a dose (RP2D).\nAssessments using Response Evaluation Criteria in Solid Tumors (RECIST) standardized imaging criteria underscored the drug’s potential to achieve durable disease control in highly advanced populations.\nOut of 14 evaluable patients, nine (64%) achieved stable disease lasting at least six months. Notably, one patient diagnosed with metastatic thyroid cancer experienced a dramatic decrease in thyroglobulin levels—a primary tumor marker associated with cancer progression. This patient has maintained stable disease for the past 12 months and continues to participate in the ongoing study.\nTTX-MC138 is designed as a first-in-class RNA therapeutic candidate to inhibit microRNA-10b (miR-10b), a biomarker and critical driver of many metastatic cancers.\nTransCode plans to transition the drug into a recently initiated Phase 2a clinical trial.\nThe upcoming phase will evaluate the efficacy of TTX-MC138 in patients who have circulating tumor DNA (ctDNA) positive colorectal cancer following curative-intent therapy.\nDr. Daniel Vlock, TransCode Consulting Clinician, said, “We continue to believe that TTX-MC138 may offer a promising therapeutic option for patients with metastatic disease who have limited treatment alternatives”.\nTransCode said that a full clinical study report is currently in progress, and the company plans to share data presentations at future scientific congresses.\nRNAZ Price Action: TransCode Therapeutics shares were up 20.91% at $6.39 during premarket trading on Wednesday. The stock is trading near its 52-week low of $5.01, according to Benzinga Pro data.\nPhoto via Shutterstock\nTo add Benzinga News as your preferred source on Google, click here.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}